High-dose, Short-term Steroid and Low-dose Long-term Steroid Use in ARDS Caused by COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-09-20

Study Completion Date

2021-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, we aimed to compare, retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom we administered short-term (3 days) high-dose (1000 mg) systemic methylprednisolone with those to whom low-dose long-term (2x 40 mg) systemic methylprednisolone was administered.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Corticosteroid Treatment on Prognosis in ARDS Secondary to Covid-19

NCT04586114

Acute Respiratory Distress Syndrome Secondary to Covid-19

UNKNOWN

Combined Use of Immunoglobulin and Pulse Steroid Therapies in Severe Covid-19 Patients

NCT06223984

Pulse Steroid and Immunoglobulins Drugs in Covid 19 Patients

COMPLETED PHASE4

Functional Capacity in Survivors of COVID-19 Related ARDS

NCT04952844

Covid19 Functional Capacity Post-intensive Care Syndrome

UNKNOWN

High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19

NCT05133635

COVID-19 Virus Infection Cytokine Storm Corticosteroid +1 more

WITHDRAWN PHASE4

Sarcopenia and Related Factors in Coronavirus Disease 2019 (COVID-19) Following Intensive Care

NCT05474157

Sarcopenia Covid19 Intensive Care Unit Acquired Weakness

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Short-term (3 Days) High-dose (1000 mg) Systemic Methylprednisolone

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

short-term (3 days) high-dose (1000 mg) systemic methylprednisolone

retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom we administered short-term (3 days) high-dose (1000 mg) systemic methylprednisolone

systemic methylprednisolone

Intervention Type BEHAVIORAL

short-term (3 days) high-dose (1000 mg) systemic methylprednisolone and low-dose long-term (2x 40 mg) systemic methylprednisolone

low-dose long-term (2x 40 mg) systemic methylprednisolone

retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom low-dose long-term (2x 40 mg) systemic methylprednisolone

systemic methylprednisolone

Intervention Type BEHAVIORAL

short-term (3 days) high-dose (1000 mg) systemic methylprednisolone and low-dose long-term (2x 40 mg) systemic methylprednisolone

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

systemic methylprednisolone

short-term (3 days) high-dose (1000 mg) systemic methylprednisolone and low-dose long-term (2x 40 mg) systemic methylprednisolone

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Between June 1, 2020 and February 1, 2021, hospitalized in the General intensive care unit of Biruni University Medical Faculty Hospital with the diagnosis of COVID 19;
* patients over 18 years of age; (for the diagnosis of COVID 19; Identification of SARS-CoV-2 by reverse transcription-polymerase chain reaction (RT-PCR) in nasopharyngeal swab or sputum samples and Abnormal lung computed tomography finding (CT) scan finding with \<90% oxygen saturation at rest (bilateral, subpleural, peripheral ground glass opacities)

Exclusion Criteria

* Patients with a diagnosis of steroid allergy or developing during treatment;
* pregnant or lactating women;
* Patients with active malignancy;
* Patients taking any immunosuppressive agent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

105 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No